This article is more than 5 years old. Information may no longer be current.
Myeloma specialists join NYU Langone Health’s Center for Blood Cancers
Click Here to Manage Email Alerts
Two nationally recognized hematology experts will help lead the multiple myeloma program at Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.
Gareth Morgan, MD, PhD, will serve as the center’s director of multiple myeloma research. Faith Davies, MD, will serve as director of the clinical myeloma program.
“We are extremely excited that [Morgan and Davies] have joined our new Center for Blood Cancers,” Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center, said in a press release. “They each have long, internationally recognized histories of leadership in myeloma research and clinical care. As an NCI-designated comprehensive cancer center, we are proud to be on the cutting edge of bringing new, improved treatments to patients with myeloma and other blood cancers.”
Morgan previously served as the director of the Myeloma Institute, deputy director of Winthrop P. Rockefeller Cancer Institute and professor of hematology at University of Arkansas for Medical Sciences. He also contributes to Myeloma Genome Project, a collaborative effort designed to identify individualized therapies based on disease subgroups. His focus at Center for Blood Cancers will be on developing new targeted treatments for high-risk variants of myeloma.
“Working with the exceptional researchers and clinicians from the Perlmutter Cancer Center, we aim to further our understanding of high-risk multiple myeloma,” Morgan said in the release. “The Center for Blood Cancers is a testament to NYU Langone’s commitment to the investigative work required to offer new solutions and therapies for patients with all types of blood cancers.”
Davies previously served as medical director of the Myeloma Institute at University of Arkansas for Medical Sciences. In that role, she oversaw patient care at a 30-bed inpatient unit, an active infusion center and several outpatient clinics.
Her research focuses on the genetic, biological and radiological theranostic markers to improve outcomes for patients with myeloma.
“I am proud to join NYU Langone’s Perlmutter Cancer Center, and lead the new Center for Blood Cancers’ Clinical Myeloma Program,” Davies said in the release. “I have a passion for patient care and hope to expand NYU Langone’s already excellent clinical practices to deliver the highest-quality treatment and clinical trials for [patients with myeloma].”